These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16644301)

  • 1. Elevated serum FGF23 concentrations in plasma cell dyscrasias.
    Stewart I; Roddie C; Gill A; Clarkson A; Mirams M; Coyle L; Ward C; Clifton-Bligh P; Robinson BG; Mason RS; Clifton-Bligh RJ
    Bone; 2006 Aug; 39(2):369-76. PubMed ID: 16644301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
    N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 and its receptors.
    Yu X; White KE
    Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal FGF23 levels in adult idiopathic phosphate diabetes.
    Laroche M; Boyer JF; Jahafar H; Allard J; Tack I
    Calcif Tissue Int; 2009 Feb; 84(2):112-7. PubMed ID: 19148564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
    Domrongkitchaiporn S; Disthabanchong S; Cheawchanthanakij R; Niticharoenpong K; Stitchantrakul W; Charoenphandhu N; Krishnamra N
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
    Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
    Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
    Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
    Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
    Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
    J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia.
    Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL
    Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak.
    Rendina D; Mossetti G; De Filippo G; Cioffi M; Strazzullo P
    J Clin Endocrinol Metab; 2006 Mar; 91(3):959-63. PubMed ID: 16352682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
    BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
    Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
    J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tumor-induced osteomalacia on the bone mineralization process.
    Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N
    Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Klotho gene, phosphocalcic metabolism, and survival in dialysis.
    Torres PU; Prié D; Beck L; De Brauwere D; Leroy C; Friedlander G
    J Ren Nutr; 2009 Jan; 19(1):50-6. PubMed ID: 19121771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.
    Fukumoto S; Yamashita T
    Bone; 2007 May; 40(5):1190-5. PubMed ID: 17276744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.